HOUSTON, Nov. 29, 2016 /PRNewswire/ -- ViraCyte, LLC, a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe infections, today announced the appointment of Brett P. Giroir, M.D. as President and Chief Executive Officer, effective immediately. Dr. Giroir is an internationally recognized expert in life sciences innovation with more than 25 years of health care and R&D leadership experience.
"ViraCyte has tremendous potential to improve patients' lives," said Giroir. "ViraCyte's product candidates demonstrate >90% effectiveness in clinical trials in patients with viral infections after stem cell transplants. In the future, we will also use our T cell platform to treat non-transplant patients who suffer from severe infections of diverse origins."
Dr. Giroir previously served as Chief Executive Officer of the Texas A&M Health Science Center and as the first physician Director of the Defense Advanced Research Projects Agency's Defense Sciences Office. During Dr. Giroir's medical career, he was the Associate Dean for Clinical Affairs at the University of Texas Southwestern Medical Center, and Chief Medical Officer at Children's Health, Dallas, where he practiced pediatric critical care medicine.
"Our primary goal for 2017 is to advance our lead candidate into pivotal trials that could result in FDA approval," said Giroir. "In parallel, we will diversify our clinical pipeline with exciting new T cell immunotherapy applications."
Dr. Giroir received his A.B. degree in biology from Harvard University, magna cum laude, and his M.D. from the University of Texas Southwestern Medical Center. He has received numerous awards including the U.S. Secretary of Defense Medal for Outstanding Public Service and the Texas A&M University System Award for Innovation. He was also a finalist for the Dallas Morning News "Texan of the Year."
About ViraCyte, LLC
ViraCyte is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe life threatening infections. ViraCyte's current products restore natural immunity against life threatening viruses in patients with severely weakened immune systems, such as adults and children who have recently undergone a hematopoietic stem cell transplant (HSCT). ViraCyte's lead T cell products are in Phase 1 and Phase 2 clinical trials, with effectiveness rates of greater than 90% in patients who have failed conventional therapy. More information can be found at www.viracyte.com.
ViraCyte is a resident company at JLABS @ TMC, Houston, Texas.
SOURCE ViraCyte, LLC